dQ&A launched the beta of our next-gen AI Insights Platform—a breakthrough natural language solution providing instant, data-driven answers for the diabetes market.
Our research with the ADA reveals severe economic impacts of COVID-19 on Americans with diabetes, including high unemployment and care rationing.
Our fourth COVID-19 survey of U.S. diabetes patients highlights persistent concerns, economic stress, and changing behaviors despite easing lockdowns.
dQ&A reveals how Walmart’s CareZone deal, low mail-order NPS scores, and a pandemic push toward home delivery are reshaping pharmacy apps for diabetes.
Our hearts are heavy at the pain felt by the Black community. We are committed to working towards a more equitable future, and we invite you to join us.
Our third COVID-19 survey of U.S. diabetes patients found high infection concern, income loss, care changes, and challenges accessing healthy food and supplies.
dQ&A analyzes telemedicine diabetes care during COVID-19—trends, patient experiences, and what's next for virtual visits amid evolving healthcare needs.
Our survey of Canada’s type 1 diabetes community reveals COVID-19’s impact on medication access, diet, exercise, hyperglycemia, and overall well-being.
Our April 2020 dQ&A survey of 4,700 U.S. diabetes patients finds supply chains largely intact yet short-term delays and risky pharmacy visits hinder refills.
